Novel combination of insulin degludec and liraglutide (IDegLira) is efficacious across the range of disease progression in type 2 diabetes

被引：0
|
作者：
Rodbard, H. W. [1 ]
Buse, J. B. [2 ]
Woo, V. C. [3 ]
Vilsboll, T. [4 ]
Langbakke, I. [5 ]
Korsholm, L. [5 ]
Gough, S. [6 ]
机构：
[1] Endocrine & Metab Consultants, Rockville, MD USA
[2] Univ N Carolina, Sch Med, Chapel Hill, NC USA
[3] Univ Manitoba, Winnipeg, MB, Canada
[4] Univ Copenhagen, Hellerup, Denmark
[5] Novo Nordisk AS, Soborg, Denmark
[6] Univ Oxford, Oxford OX1 2JD, England
来源：
DIABETOLOGIA | 2014年 / 57卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
835
引用
收藏
页码：S338 / S339
页数：2
相关论文
共 50 条
  • [31] An indirect treatment comparison of the efficacy of insulin degludec/liraglutide (IDegLira) and insulin glargine/lixisenatide (iGlarLixi) in patients with type 2 diabetes uncontrolled on basal insulin
    Evans, Marc
    Billings, Liana K.
    Hakan-Bloch, Jonas
    Slothuus, Ulla
    Abrahamsen, Trine J.
    Andersen, Andreas
    Jansen, Jeroen P.
    JOURNAL OF MEDICAL ECONOMICS, 2018, 21 (04) : 340 - 347
  • [32] Effectiveness of insulin degludec/liraglutide versus insulin degludec/insulin aspart in Japanese patients with type 2 diabetes
    Junko Oya
    Tomoko Nakagami
    Yukiko Hasegawa
    Yuichiro Kondo
    Aki Katamine
    Mika Shimizu
    Ryo Kubota
    Rika Suda
    Tetsuya Babazono
    Diabetology International, 2024, 15 : 237 - 243
  • [33] Insulin degludec/liraglutide (IDegLira) was effective across a range of dysglycaemia and body mass index categories in the DUAL V randomized trial
    Lingvay, Ildiko
    Harris, Stewart
    Jaeckel, Elmar
    Chandarana, Keval
    Ranthe, Mattis F.
    Jodar, Esteban
    DIABETES OBESITY & METABOLISM, 2018, 20 (01): : 200 - 205
  • [34] Insulin degludec/liraglutide in type 2 diabetes: a profile of its use
    Heo, Young-A
    DRUGS & THERAPY PERSPECTIVES, 2020, 36 (06) : 219 - 229
  • [35] Insulin degludec/liraglutide in type 2 diabetes: a profile of its use
    Young-A Heo
    Drugs & Therapy Perspectives, 2020, 36 : 219 - 229
  • [36] Insulin Degludec/Liraglutide (Xultophy 100/3.6) for Type 2 Diabetes
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2017, 59 (1529): : 147 - 149
  • [37] Pharmacokinetic evaluation of fixed-ratio combination of insulin degludec and liraglutide in the treatment of type 2 diabetes
    Lamos, Elizabeth Mary
    Davis, Stephen N.
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2016, 12 (10) : 1225 - 1232
  • [38] THE EFFECT OF INSULIN DEGLUDEC IN COMBINATION WITH LIRAGLUTIDE AND METFORMIN IN PATIENTS WITH TYPE 2 DIABETES REQUIRING TREATMENT INTENSIFICATION
    Aroda, V.
    Bailey, T.
    Cariou, B.
    Kumar, S.
    Leiter, L.
    Raskin, P.
    Zacho, J.
    Bandier, M.
    Philis-Tsimikas, A.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2014, 106 : S261 - S262
  • [39] The effect of insulin degludec in combination with liraglutide and metformin in patients with type 2 diabetes requiring treatment intensification
    Aroda, V. R.
    Bailey, T.
    Cariou, B.
    Kumar, S.
    Leiter, L. A.
    Raskin, P.
    Zacho, J.
    Bandier, M.
    Philis-Tsimikas, A.
    DIABETOLOGIA, 2014, 57 : S68 - S68
  • [40] Reductions in HbA1c, hypoglycaemia rates and insulin requirements in response to a combination of insulin degludec and liraglutide (IDegLira) in patients with Type 2 diabetes are independent of body mass index
    Viljoen, A.
    Rodbard, H. W.
    Woo, V. C.
    Vilsboll, T.
    Korsholm, L.
    Gough, S. C. L.
    DIABETIC MEDICINE, 2015, 32 : 75 - 75
12345